The cannabis industry is booming, with $6.7 billion in sales in North America for 2016. And sales are only going to increase, with analysts projecting $20 billion in sales by 2020.
That's nearly a 200% increase in just four years.
That's why each week, we provide Money Morning readers with the top marijuana stocks to watch.
But before getting into the top cannabis stocks on our watch list, we wanted to make sure our readers were aware of the risks of investing in pot stocks.
The first issue is marijuana is still illegal under federal law.
Even though some states have legalized both recreational and medical marijuana, the federal status of marijuana makes pot stocks speculative investments for now.
Also, many marijuana stocks trade on over-the-counter markets, which aren't regulated like the New York Stock Exchange (NYSE) or Nasdaq. On top of all that, most marijuana stocks are penny stocks, which are notoriously risky.
But marijuana legalization is more than just a trend, which is why we're researching these stocks so closely. According to an October 2016 Gallup poll, 60% of Americans support marijuana legalization.
And because 28 states and Washington, D.C., have some form of marijuana legalization, it's only a matter of when and not if medical marijuana is legalized across America.
After that, legalized recreational use in each state won't be far behind.
With that in mind, the first marijuana stock on our watch list this week is Green Cures & Botanical Distribution Inc. (OTCMKTS: GRCU). Green Cures sells medicinal and nutritional body care products.
And we're watching GRCU this week because it just announced a joint partnership with Kushtown Soda on March 30.
Kushtown is based in California and specializes in cannabis-infused water and cannabis-infused sodas. According to Marijuanastocks.com, the company has products in over 200 medical marijuana dispensaries and has 20 different varieties of medicated soda.
BRILLIANT: Average Americans Are Becoming Marijuana Millionaires
The partnership will help increase brand awareness for Green Cure, which has specialty products like hemp soap, hemp lip balm, and hemp-dissolving sugar cubes.
The news seemed to help the GRCU stock price climb. Between March 31 and April 6, it shot up nearly 20%.
But the next marijuana stock on our list has already climbed 70% so far in 2017 and could keep climbing because of endorsements from numerous athletes and celebrities...
The Top Marijuana Stock on Our Watch List
[mmpazkzone name="in-story" network="9794" site="307044" id="137008" type="4"]
Through its subsidiary HempLife Today, Ubiquitech Software Corp. (OTCMKTS: UBQU). sells cannabidiol (CBD) products like tinctures, concentrates, power, vape oil, and capsules.
And according to MarijuanaStocks.com, Ubiquitech believes notable athletes and celebrities endorsing CBD over the last year will help increase awareness of CBD products. Former Denver Broncos quarterback Jake Plummer, UFC fighter Nate Diaz, and movie star Whoopi Goldberg have all endorsed CBD products.
According to a company statement on April 4, Operation Managers Luke Dreyer said CBD awareness is now above 5% among the general public.
"This is what boosts our monthly and quarterly sales apart from our other major marketing initiatives. This is free publicity for a product that people want and you can't get better than that," Dreyer said.
You see, one of the challenges for Ubiquitech is some people believe anything related to the marijuana industry is illegal. That's because the Controlled Substances Act of 1970 classified all forms of cannabis as a Schedule I drug.
But CBD hemp oil is made from plants with only trace amounts of THC (the psychoactive chemical in marijuana). That means HempLife Today does not sell products made with marijuana, and its products are legal in all 50 states.
As athletes and celebrities bring increased awareness to CBD products, this should be a boom for Ubiquitech's sales.
The UBQU stock price has climbed over 70% so far in 2017.
While we're focusing on GRCU and UBQU this week, our readers know there are a lot of other ways to play the booming cannabis industry...
The vote across America for marijuana legalization is expected to create one of the biggest wealth grabs in history, transforming everyday Americans into millionaires overnight.
That's why Money Morning Director of Technology & Venture Capital Research Michael A. Robinson has created the "bible of weed investing" for Money Morning readers.
Who Is Marijuana Stock Guru Michael Robinson?
Michael is one of our most prominent and respected investing "gurus" here at Money Map Press - and for good reason. He is one of the top financial analysts working today. Make no mistake: Michael's ideas are completely his own. He's a true original. He works solely for Money Map Press... and receives absolutely no compensation from companies he writes about.
His book "Overdrawn: The Bailout of American Savings" was a prescient look at the anatomy of the nation's S&L crisis, long before the word "bailout" became part of our daily lexicon. He's a Pulitzer Prize-nominated writer and reporter, lauded by the Columbia Journalism Review for his aggressive style.
Michael's 30-year track record as a leading tech analyst has garnered him rave reviews, too.
As editor of the financial newsletter American Wealth Underground, Michael amassed an amazing track record using rigorous investing. The first analyst to uncover the rare earth mineral crisis, he amassed cumulative gains of 990% for his readers in just 16 months.
His research is world class, too. The Oakland Tribune, Detroit News, The San Francisco Examiner, The Kansas City Times, Wealth Magazine, and American Banker all publish his reporting. He has appeared on Larry King's syndicated radio show.
Robinson has an honors economics degree from the University of Missouri at Columbia with a minor in journalism.
And as a service to Money Morning readers, we're now making available a 90-page cannabis investing guide called The Roadmap to Marijuana Millions.
This "bible of weed investing" reveals the world's top marijuana stocks every serious investor should consider right now.
Normally valued at $499, it can be yours absolutely free. To learn how to get your free copy, click here.
This offer is only available to the first 500 people who respond today. So please go here now to reserve your copy.